Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Pros

Reuters
Mar 16
March 16 (Reuters) - Monte Rosa Therapeutics Inc ::
*MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
*MONTE ROSA THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY OF MRT-2359 WITH APALUTAMIDE IN Q3 2026
*MONTE ROSA THERAPEUTICS INC - ENTERS SUPPLY AGREEMENT WITH JOHNSON & JOHNSON FOR PHASE 2 MCRPC STUDY STARTING Q3 2026
*MONTE ROSA THERAPEUTICS INC - TO CONDUCT AND SPONSOR TRIAL; JOHNSON & JOHNSON TO SUPPLY ERLEADA

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 16-MAR-202611:00:01.857 GMT

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10